Joseph Eron (@joseph_eron) 's Twitter Profile
Joseph Eron

@joseph_eron

ID: 2980545639

calendar_today16-01-2015 02:09:35

281 Tweet

579 Followers

63 Following

Danilo Bacic Lima, MD (@danbacic) 's Twitter Profile Photo

I asked ChatGPT to write a poem about the life of an ID Fellow. I gave it some information about a typical ID doc workday and asked it to make it witty and funny. I asked it to communicate enthusiasm for the specialty and recruit more docs for ID. Here’s what it came up with:

Joseph Eron (@joseph_eron) 's Twitter Profile Photo

Have to agree with Jose R Arribas though more data to come with DTG/DRVboosted. Two very high barrier agents. LEN and CAB both are not in that category. CROI will be great this year-go if you can

Joseph Eron (@joseph_eron) 's Twitter Profile Photo

Gift wrapped "cure package" for hard to reach (wait no - HARDLY reached) patients. Another Infectious Disease service with incredible down stream value to the patient, healthcare system and public health (but no wRVUs)

Joseph Eron (@joseph_eron) 's Twitter Profile Photo

Yesterday in clinic we saw our one of our older patients living with HIV for 30 + years who just had their first great, great grandchild. Seriously, who would have dreamed that up 30 years ago.

Joseph Eron (@joseph_eron) 's Twitter Profile Photo

Amen! Our downstream VALUE to patients, health care systems and public health is unrecognized or unappreciated and therefore uncompensated. What "wRVU" is assigned to curing HCV (see last tweet). atCVDH(if heaven has twitter) would likely have advice.pnhp.org/news/i-was-doi…

Liz Highleyman (@lizhighleyman) 's Twitter Profile Photo

Potentially the next step in the evolution of #HIV treatment: Gilead Sciences' lenacapavir (Sunlenca) + 2 broadly neutralizing antibodies (teropavimab & zinlirvimab) maintained viral suppression for 6 months, Joseph Eron of UNC-Chapel Hill reported at #CROI2023 poz.com/article/sunlen…

Institute for Global Health & Infectious Diseases (@uncglobalhealth) 's Twitter Profile Photo

National guidelines may have played a role in #equitable access to new therapy. #racial #disparities #HIV #ART Check out Lauren Zalla’s work guided by Ada Adimora and Joseph Eron... The❓now is how ➡️unc.live/3JjgFvr

National guidelines may have played a role in  #equitable access to new therapy. #racial #disparities #HIV #ART Check out <a href="/LaurenZalla/">Lauren Zalla</a>’s work guided by <a href="/AdaAdimora/">Ada Adimora</a> and <a href="/joseph_eron/">Joseph Eron</a>... The❓now is how ➡️unc.live/3JjgFvr
Joseph Eron (@joseph_eron) 's Twitter Profile Photo

Critically important paper for HIV providers as MPox potentially becomes a uncommon endemic infection in people who have risk. Also vaccinate people with risk! pubmed.ncbi.nlm.nih.gov/36828001/

Clinical Care Options (@cco_education) 's Twitter Profile Photo

Join Joseph Eron and Princy N. Kumar, MD on 4/11 in DC for 'CROI 2023 Update: What Did We Learn?'. Earn 2.50 AMA, ANCC, and ACPE credits. Dinner provided by CCO. Register for free: bit.ly/3LZMjQt

Michelle Floris-Moore, MD, MS, FIDSA (@mfm_id_md) 's Twitter Profile Photo

Looking forward to the launch of this innovative training program UNC Division of Infectious Diseases . Applicants for combined ID/EIS training need to apply separately to EIS and ID programs. Apply now for EIS. Application period open through June 5, 2023. Joe Tucker, MD David van Duin David Alain Wohl

Joseph Eron (@joseph_eron) 's Twitter Profile Photo

Large NIH study, Led by Steve Grinspoon and Pam Douglas, in partnership with ACTG, demonstrates that statin therapy in low and mod CVD-risk people with HIV decreases CVD outcomes. ACTG Network niaid.nih.gov/news-events/da…

Rachel Ann Bender Ignacio, MD MPH (@drbenderignacio) 's Twitter Profile Photo

Thrilled to be a part of this ACTG Network #COVID19 UW Positive Research Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 | Annals of Internal Medicine acpjournals.org/doi/10.7326/M2…